Related references
Note: Only part of the references are listed.Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
Aristeidis Chaidos et al.
BLOOD (2013)
Reply to Response to CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012;97(7):1110-1114
Teresa Paino et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2013)
Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
Jaroslaw Jacak et al.
JOURNAL OF BIOTECHNOLOGY (2013)
Multipotential Differentiation of Human Urine-Derived Stem Cells: Potential for Therapeutic Applications in Urology
Shantaram Bharadwaj et al.
STEM CELLS (2013)
The peripheral CD138+population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients
David Chiron et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher et al.
CLINICAL CANCER RESEARCH (2012)
Characterization of potential CD138 negative myeloma stem cells
Jacob H. Christensen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Teresa Paino et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
N. Hosen et al.
LEUKEMIA (2012)
CD19-CD45low/-CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
D. Kim et al.
LEUKEMIA (2012)
Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model
E. Van Valckenborgh et al.
LEUKEMIA (2012)
ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets
Yuchun Luo et al.
STEM CELLS (2012)
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
Jana Jakubikova et al.
BLOOD (2011)
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Piyush B. Gupta et al.
CELL (2011)
Can multiple myeloma become a curable disease?
Jesus F. San-Miguel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
B. Paiva et al.
LEUKEMIA (2011)
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
Alexander Roesch et al.
CELL (2010)
Bone marrow stromal cell interaction reduces Syndecan-1 expression and induces kinomic changes in myeloma cells
Gwenny M. Fuhler et al.
EXPERIMENTAL CELL RESEARCH (2010)
Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma
S. Reid et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2010)
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
Enrique M. Ocio et al.
BLOOD (2009)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells
Hangwen Li et al.
CANCER RESEARCH (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
Radek Spisek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Anjli Kukreja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
S Yaccoby
CLINICAL CANCER RESEARCH (2005)
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
Q Chen et al.
BLOOD (2005)
Multifunctional role of Erk5 in multiple myeloma
X Carvajal-Vergara et al.
BLOOD (2005)
Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia
NC Gutéerrez et al.
LEUKEMIA (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
The SCID-rab model:: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
K Yata et al.
LEUKEMIA (2004)
Bone marrow immunohistology of plasma cell neoplasms
A Wei et al.
JOURNAL OF CLINICAL PATHOLOGY (2003)
Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells
S Greenstein et al.
EXPERIMENTAL HEMATOLOGY (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Plasma cells: finding new light at the end of B cell development
KL Calame
NATURE IMMUNOLOGY (2001)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
S Zhou et al.
NATURE MEDICINE (2001)
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
GG Wulf et al.
BLOOD (2001)
Interleukin-6 is a growth factor for nonmalignant human plasmablasts
G Jego et al.
BLOOD (2001)
Share Paper
